RBC Sees Positives for Pharmacyclics Amid News of Rejected Offer for Onyx from Amgen
July 01, 2013 at 15:47 PM EDT
Shares of Pharmacyclics (NASDAQ: PCYC ) have rallied about 7 percent Monday following news Onyx Pharma (NASDAQ: ONXX ) rejected a $120/share cash bid from Amgen (NASDAQ: AMGN ). RBC Capital's Michael Yee called Pharmacyclics the most attractive target following the Onyx news. The analyst cited the
